- Email: [email protected]
5164296 Assay methods involving ouabain
162
Bezoar bovis Borneol-ethanol tion.
PATENT ABSTRACTS
and moschus powders. the solution and, the Gelating solu-
ouabain in the subject are disclosed, along with an antibody having binding specificity for ouabain.
5164389
5164293 MONOCLONAL ANTIBODY FOR DETECTING HTLV-I, HTLV-II AND STLV-I VIRUSES David E Hotheinz, Gary Toedter, Lori Charie, Samuel R Pearlman assigned to Coulter Corporation A hybrid cell line is provided which is capable of producing monoclonal antibodies which binds to HTLV-I and HTLV-II core antigens ~24 and ~53; but does not bind the ~19 core antigen. The antibody also binds to core antigens of simian Tcell leukemia virus Type I (STLV-I). The monoclonal antibody is identified as the KC-88 monoclonal antibody. The cell line which produces the KC-88 monoclonal antibody has been deposited in the American Type Culture Collection, Rockville, Md. and assigned A.T.C.C. Deposit No. HB 10562.
5164296 ASSAY METHODS INVOLVING OUABAIN Mordecai P Blaustein, John M Hamlyn, Douglas Harris, James H Ludens, William R Mathews, Jed F Fisher, Frederic Mandel, Donald W DuCharme assigned to University of Maryland at Baltimore Methods for diagnosing pre-hypertension, hypertension, congestive cardiomyopathy, renal failure, salt-sensitivity and adenomas and endocrine cell hyperplasias are disclosed. Also disclosed are methods for monitoring hypertension therapy, congestive cardiomyopathy therapy, renal failure therapy and adenoma and endocrine call hyperplasia therapy. These methods involve using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject. Additionally, methods for treating a hypertensive subject by inducing passive or active immunity to human
ANTHELMINTIC BIOCONVERSION PRODUCTS Shieh-Shung Inc
T Chen assigned to Merck & Co
There are disclosed new compound with significant antiparasitic activity which are prepared by fermenting the compounds paraherquamide or dihydroparaherquamide in a novel microorganism identified as Cunninghamella blakesleeana MF-4415. The compounds are best realized in the following structural formulae: See Potent for Chemicn[ Sfructure (II) MeMeAOONHOMeMeONMeHON MeMeAOONMeOH (III) HOMeMeONMeONMeOH (IV) wherein A is either a single or a double bond. The paraherquamide compound is modified by the microorganism by ring hydroxylation or ketonization. The compounds are significant antiparasitic and anthelmintic agents and compositions for that use are also disclosed.
5164487 MANUFACTURING INTRAVENOUS TOLERABLE IMMUNOGLOBULIN-G PREPARATION Norbert Kothe, Dieter Rudnick, Detlef Piechaczek, Herwald Klein, Detlef Rohm, Michael Kloft, Kronberg, Federal Republic Of Germany assigned to Biotest Pharma GmbH Method of manufacturing an intravenously tolerable immunoglobulin-G preparation that is free of aggregates, vasoactive substances and proteolytic enzymes and accordingly appropriate for all types of patients, especially immunosuppressed patients, from a starting material that contains immunoglobulin G but from which the coagulation factors have been removed. The starting material is treated with 0.4 to 1.5% by volume of octanoic acid and then chromatographed, especially on an ion or cation exchanger or hydrophobic matrix.
Bezoar bovis Borneol-ethanol tion.
PATENT ABSTRACTS
and moschus powders. the solution and, the Gelating solu-
ouabain in the subject are disclosed, along with an antibody having binding specificity for ouabain.
5164389
5164293 MONOCLONAL ANTIBODY FOR DETECTING HTLV-I, HTLV-II AND STLV-I VIRUSES David E Hotheinz, Gary Toedter, Lori Charie, Samuel R Pearlman assigned to Coulter Corporation A hybrid cell line is provided which is capable of producing monoclonal antibodies which binds to HTLV-I and HTLV-II core antigens ~24 and ~53; but does not bind the ~19 core antigen. The antibody also binds to core antigens of simian Tcell leukemia virus Type I (STLV-I). The monoclonal antibody is identified as the KC-88 monoclonal antibody. The cell line which produces the KC-88 monoclonal antibody has been deposited in the American Type Culture Collection, Rockville, Md. and assigned A.T.C.C. Deposit No. HB 10562.
5164296 ASSAY METHODS INVOLVING OUABAIN Mordecai P Blaustein, John M Hamlyn, Douglas Harris, James H Ludens, William R Mathews, Jed F Fisher, Frederic Mandel, Donald W DuCharme assigned to University of Maryland at Baltimore Methods for diagnosing pre-hypertension, hypertension, congestive cardiomyopathy, renal failure, salt-sensitivity and adenomas and endocrine cell hyperplasias are disclosed. Also disclosed are methods for monitoring hypertension therapy, congestive cardiomyopathy therapy, renal failure therapy and adenoma and endocrine call hyperplasia therapy. These methods involve using an antibody having binding specificity to ouabain to immunologically measure the level of human ouabain in body fluid or tissue of a subject. Additionally, methods for treating a hypertensive subject by inducing passive or active immunity to human
ANTHELMINTIC BIOCONVERSION PRODUCTS Shieh-Shung Inc
T Chen assigned to Merck & Co
There are disclosed new compound with significant antiparasitic activity which are prepared by fermenting the compounds paraherquamide or dihydroparaherquamide in a novel microorganism identified as Cunninghamella blakesleeana MF-4415. The compounds are best realized in the following structural formulae: See Potent for Chemicn[ Sfructure (II) MeMeAOONHOMeMeONMeHON MeMeAOONMeOH (III) HOMeMeONMeONMeOH (IV) wherein A is either a single or a double bond. The paraherquamide compound is modified by the microorganism by ring hydroxylation or ketonization. The compounds are significant antiparasitic and anthelmintic agents and compositions for that use are also disclosed.
5164487 MANUFACTURING INTRAVENOUS TOLERABLE IMMUNOGLOBULIN-G PREPARATION Norbert Kothe, Dieter Rudnick, Detlef Piechaczek, Herwald Klein, Detlef Rohm, Michael Kloft, Kronberg, Federal Republic Of Germany assigned to Biotest Pharma GmbH Method of manufacturing an intravenously tolerable immunoglobulin-G preparation that is free of aggregates, vasoactive substances and proteolytic enzymes and accordingly appropriate for all types of patients, especially immunosuppressed patients, from a starting material that contains immunoglobulin G but from which the coagulation factors have been removed. The starting material is treated with 0.4 to 1.5% by volume of octanoic acid and then chromatographed, especially on an ion or cation exchanger or hydrophobic matrix.